BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31025390)

  • 21. Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma.
    Voskoboynik M; Mar V; Mailer S; Colebatch A; Fennessy A; Logan A; Hewitt C; Cebon J; Kelly J; McArthur G
    Pigment Cell Melanoma Res; 2016 Mar; 29(2):222-8. PubMed ID: 26643848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
    van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
    J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
    Dankort D; Curley DP; Cartlidge RA; Nelson B; Karnezis AN; Damsky WE; You MJ; DePinho RA; McMahon M; Bosenberg M
    Nat Genet; 2009 May; 41(5):544-52. PubMed ID: 19282848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Symmetric Eczematous Eruption Harboring Thousands of Melanocytic Lesions.
    Ratushny V; Kraft S; Moschella SL; Duncan LM; Lawrence DP; Tsao H
    JAMA Dermatol; 2016 Sep; 152(9):1021-4. PubMed ID: 27192392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
    Sigalotti L; Fratta E; Parisi G; Coral S; Maio M
    Br J Cancer; 2011 Jul; 105(2):327-8. PubMed ID: 21694724
    [No Abstract]   [Full Text] [Related]  

  • 28. Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma.
    Kaplon J; Hömig-Hölzel C; Gao L; Meissl K; Verdegaal EM; van der Burg SH; van Doorn R; Peeper DS
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):640-52. PubMed ID: 24703243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KLF9-dependent ROS regulate melanoma progression in stage-specific manner.
    Bagati A; Moparthy S; Fink EE; Bianchi-Smiraglia A; Yun DH; Kolesnikova M; Udartseva OO; Wolff DW; Roll MV; Lipchick BC; Han Z; Kozlova NI; Jowdy P; Berman AE; Box NF; Rodriguez C; Bshara W; Kandel ES; Soengas MS; Paragh G; Nikiforov MA
    Oncogene; 2019 May; 38(19):3585-3597. PubMed ID: 30664687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heavily Pigmented Epithelioid Melanoma With Loss of Protein Kinase A Regulatory Subunit-α Expression.
    Cohen JN; Spies JA; Ross F; Bohlke A; McCalmont TH
    Am J Dermatopathol; 2018 Dec; 40(12):912-916. PubMed ID: 29771690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.
    van den Hurk K; Balint B; Toomey S; O'Leary PC; Unwin L; Sheahan K; McDermott EW; Murphy I; van den Oord JJ; Rafferty M; FitzGerald DM; Moran J; Cummins R; MacEneaney O; Kay EW; O'Brien CP; Finn SP; Heffron CC; Murphy M; Yela R; Power DG; Regan PJ; McDermott CM; O'Keeffe A; Orosz Z; Donnellan PP; Crown JP; Hennessy BT; Gallagher WM
    Melanoma Res; 2015 Jun; 25(3):189-99. PubMed ID: 25746038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SOX10 Expression as Well as BRAF and GNAQ/11 Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms From Uveal Melanomas.
    Mori T; Sukeda A; Sekine S; Shibata S; Ryo E; Okano H; Suzuki S; Hiraoka N
    Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5445-5451. PubMed ID: 29059311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pigmented epithelioid melanocytoma arising from a teratoma of a Carney complex patient.
    Ichiki T; Ito T; Oishi H; Kato K; Oda Y; Nakahara T
    J Obstet Gynaecol Res; 2024 Feb; 50(2):266-269. PubMed ID: 37985470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanocytic Skin Neoplasms: What Lesson From Genomic Aberrations?
    Urso C
    Am J Dermatopathol; 2019 Sep; 41(9):623-629. PubMed ID: 31433323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
    Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
    Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential.
    van Poppelen NM; Vaarwater J; Mudhar HS; Sisley K; Rennie IG; Rundle P; Brands T; van den Bosch QCC; Mensink HW; de Klein A; Kiliç E; Verdijk RM
    Ophthalmology; 2018 Jun; 125(6):904-912. PubMed ID: 29371009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case Report of a Large Pigmented Epithelioid Melanocytoma With Suspected Lymph Node Metastases.
    Akita R; Sowa Y; Morita D; Numajiri T
    Eplasty; 2016; 16():e33. PubMed ID: 28066518
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.